3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
102
Carcinoma, Intraductal, Noninfiltrating
12
Breast Carcinoma In Situ
10
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms, Male
6
Neoplasms
5
Glioblastoma
5
Central Nervous System Neoplasms
5
Prostatic Neoplasms
4
Gliosarcoma
4
Inflammatory Breast Neoplasms
3
Glioma
3
Brain Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Breast Cancer Female
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Risk Reduction Behavior
1
Interventions
Fulvestrant
5
Letrozole
3
Capecitabine
3
ribociclib
2
exemestane
2
dalpiciclib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
Anastrozole
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
palbociclib
1
margetuximab
1
irinotecan sucrosofate
1
fluzoparib
1
abemaciclib
1
Vinorelbine
1
Trastuzumab
1
Tamoxifen
1
Paclitaxel
1
Liposomes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Metastatic
×
Tamoxifen
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts